menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Cladribine Receives Positive CHMP Opinion for Relapsing MS Treatment

ReachMD Healthcare Image
Read full article
Choose a format
Media formats available:
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Related
Comments
  • Overview

    Merck KGaA, Darmstadt, Germany announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of Cladribine Tablets (proposed tradename MAVENCLAD[TM]) for the treatment of relapsing forms of multiple sclerosis (RMS) in patients with high disease activity.

    To learn more about current and future treatment options for MS patients, click here

Facebook Comments

Recommended
Details
Related
Comments
  • Overview

    Merck KGaA, Darmstadt, Germany announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of Cladribine Tablets (proposed tradename MAVENCLAD[TM]) for the treatment of relapsing forms of multiple sclerosis (RMS) in patients with high disease activity.

    To learn more about current and future treatment options for MS patients, click here

Facebook Comments

Schedule19 May 2022
Webpack App